Secondary prevention of cardiovascular disease with vorapaxar: a new era of 3-drug antiplatelet therapy?

Abstract

In May 2014, the US Food and Drug Administration (FDA) approved vorapaxar (Zontivity; Merck), an oral antiplatelet agent, for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or peripheral arterial disease.1 The FDA acted after a 10 to 1 vote in favor of approval in January 2014 by the Cardiovascular and… (More)
DOI: 10.1001/jamainternmed.2014.5802

Topics

  • Presentations referencing similar topics